Entrada Therapeutics, Inc.
TRDA Healthcare Biotechnology
Entrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024. In the quarter to June 2026, revenue fell 54.0%, EPS grew 2.88% and free cash flow fell 9.10%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TRDA
Entrada Therapeutics, Inc. (TRDA) Altman Z-score
Entrada Therapeutics, Inc.'s Altman Z-score for fiscal 2025 is 2.15, in the grey zone (1.81–2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 2.15 | (3.08) |
| FY2024 | 5.23 | 3.70 |
| FY2023 | 1.53 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.75 | — | 0.90 | |
| Retained earnings / total assets | (0.72) | — | −1.01 | |
| EBIT / total assets | (0.42) | — | −1.38 | |
| Market value of equity / total liabilities | 5.97 | — | 3.58 | |
| Sales / total assets | 0.07 | — | 0.07 | |
| Altman Z-score | Grey zone | 2.15 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 4.24 | ||
Z and Z″ put Entrada Therapeutics, Inc. in different zones: grey zone by Z, safe zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| UPB Upstream Bio, Inc. compare | 61.0× |
| ACOG Alpha Cognition Inc. compare | 2.5× |
| TRDA Entrada Therapeutics, Inc. | 2.2× |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | 1.0× |
| ADCT ADC Therapeutics SA compare | −6.7× |
| STRO Sutro Biopharma, Inc. compare | −9.6× |
| YARW Yarrow Bioscience, Inc compare | −31.1× |
| ELDN Eledon Pharmaceuticals, Inc. compare | — |
| SION Sionna Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets